2026-09-16 14:13:55 UTC#321312newconfirmednews
Gilead Sciences (GILD) stock news
Gilead Sciences (GILD) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-09-16 13:23:10 UTC#320990newconfirmednews
Assembly Biosciences advances antiviral pipeline to Phase II with Gilead collaboration, cash runway to 2029
2026-09-15 22:52:53 UTC#317389newconfirmednews
Lexeo Therapeutics pivots to T-cell engager therapies following Ouro Medicines acquisition and Gilead partnership
quartrimportance 0.40trust 0.50Lexeo Therapeutics, Inc. +0.40Ouro Medicines +0.30Gilead Sciences, Inc. +0.30
2026-09-15 16:42:11 UTC#315595updateconfirmednews
Gilead Sciences highlights HIV portfolio momentum with strong Yeztugo uptake and upcoming anito-cel launch
2026-09-15 16:01:11 UTC#315261newreportedanalysis
Gilead Sciences growth strategy centers on HIV, oncology, and immunology portfolio expansion
2026-09-15 15:12:13 UTC#314928duplicateconfirmednews
Gilead Sciences and PAHO partner to expand access to HIV drug lenacapavir in Latin America and Caribbean
reutersimportance 0.30trust 0.90Gilead Sciences, Inc. +0.30Pan American Health Organization +0.30Lenacapavir +0.30
2026-09-15 15:10:00 UTC#314867newconfirmednews
Gilead Sciences partners with PAHO to expand access to HIV prevention drug lenacapavir in Latin America and Caribbean
reutersimportance 0.40trust 0.90Gilead Sciences, Inc. +0.30Pan American Health Organization +0.30Lenacapavir +0.30
2026-09-13 11:50:00 UTC#303548newconfirmedpress release
Gilead and Merck's Sacituzumab Govitecan plus Pembrolizumab fails primary endpoints in Phase 3 EVOKE-03 NSCLC trial
pr newswireimportance 0.60trust 0.90Gilead Sciences, Inc. -0.50Merck & Co., Inc. -0.20EVOKE-03/KEYNOTE-D46 -0.50
2026-09-11 07:14:46 UTC#297073newconfirmednews
HSBC raises Gilead Sciences (GILD) price target to $175; Biktarvy holds 52% U.S. HIV market share
tradingviewimportance 0.40trust 0.50Gilead Sciences, Inc. +0.50HSBC Holdings plc +0.40Merck & Co., Inc. +0.20+2 entities
2026-09-10 15:59:50 UTC#293566newconfirmednews
Gilead Sciences (GILD) growth driven by HIV franchise performance, oncology pipeline, and acquisitions
2026-09-08 20:49:00 UTC#283562newconfirmednews
Assembly Biosciences exercises U.S. profit-share option for Gilead herpes program, expects $75M payment
dow_jonesimportance 0.50trust 0.90Assembly Biosciences, Inc. +0.50Gilead Sciences, Inc. +0.40Jason Okazaki 0
2026-08-27 22:56:00 UTC#232139duplicateconfirmednews
FDA approves Gilead Sciences' Bixlenvo as once-daily HIV treatment for virologically suppressed adults
dow_jonesimportance 0.30trust 0.90Gilead Sciences, Inc. +0.50Food and Drug Administration +0.20Bixlenvo +0.60+2 entities
2026-08-27 22:02:23 UTC#231943duplicateconfirmednews
FDA approves Gilead's Bixlenvo, a once-daily HIV combination pill for suppressed adults
reutersimportance 0.40trust 0.90Gilead Sciences, Inc. +0.60U.S. Food and Drug Administration 0Bixlenvo +0.60+2 entities
2026-08-27 21:50:41 UTC#231908newconfirmednews
FDA approves Gilead Sciences' once-daily oral combination pill for HIV treatment
2026-08-27 21:50:23 UTC#231909duplicateconfirmednews
FDA approves Gilead Sciences' Bixlenvo as once-daily HIV treatment for suppressed adults
reutersimportance 0.50trust 0.90Gilead Sciences, Inc. +0.60Bixlenvo +0.60U.S. Food and Drug Administration +0.20
2026-08-27 21:49:18 UTC#231917duplicateconfirmednews
FDA approves Gilead's new daily HIV pill for patients on stable regimens
cnbcimportance 0.40trust 0.80Gilead Sciences, Inc. +0.50U.S. Food and Drug Administration 0Biktarvy +0.10
2026-08-24 20:43:00 UTC#214302duplicateconfirmednews
Lakefront Biotherapeutics Receives FDA Orphan Drug Designation for Gamgertamig to Treat Pemphigus
dow_jonesimportance 0.30trust 0.90Lakefront Biotherapeutics +0.50Food and Drug Administration +0.40Gilead Sciences +0.30+2 entities
2026-08-24 11:21:18 UTC#211730newconfirmednews
EU approves Gilead's Trodelvy and Merck's Keytruda combination for first-line breast cancer
2026-08-23 23:15:05 UTC#209789newconfirmedanalysis
Gilead Q2 2026 Revenue Up 10% to $7.8B on HIV Growth; Full-Year Guidance Raised
2026-08-14 16:27:07 UTC#179212newconfirmednews